Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : YG-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $16.3 million
Deal Type : Series A Financing
YGION Biomedical Announces €15 Million Series A Financing for Cancer Immunotherapies
Details : The proceeds will be used to further develop YGION's unique YGNITETM technology platform and advance the lead program YG-01, a cancer vaccine, into preclinical and clinical development.
Product Name : YG-01
Product Type : Vaccine
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : YG-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $16.3 million
Deal Type : Series A Financing